Archive for March, 2012

ScienceDaily (Mar. 29, 2012) Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute (UOHI), in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet.

The article "Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial," reports on the use of a simple cheek swab test, the Spartan RX CYP2C19, performed by nurses at the patient's bedside. This revolutionary technology allows doctors to rapidly identify patients with a genetic variant known as CYP2C19*2. Cardiac stent patients with this variant are at risk of reacting poorly to standard anti-platelet therapy with Plavix (clopidogrel).

The study demonstrated that tailored drug treatment therapy made possible by the genetic testing successfully protected all of the patients with the at-risk genetic variant from subsequent adverse events, while 30 per cent of patients treated with standard therapy did not receive adequate protection.

"For the first time in medicine, nurses were able to perform DNA testing at the patient's bedside. This is a significant step towards the vision of personalized medicine," said Dr. Derek So, Interventional Cardiologist at the University of Ottawa Heart Institute (UOHI), and principal investigator of the RAPID GENE study.

Study Details

The RAPID GENE study enrolled 200 patients who were being treated with cardiac stenting for an acute coronary syndrome or stable angina. Patients were randomized to a treatment strategy of rapid point-of-care genotyping and Effient (prasugrel) for CYP2C19*2 carriers, or to standard therapy with Plavix (clopidogrel). The Spartan RX CYP2C19 bedside DNA test was performed by nurses who received a 30-minute training session, but had no prior laboratory training. The test had a sensitivity of 100% and a specificity of 99.4% compared with DNA sequencing. For CYP2C19*2 carriers, treatment with prasugrel completely eliminated High on-treatment Platelet Reactivity (HPR). HPR is a marker for patients at risk of complications after stenting. In contrast, 30.4% of carriers receiving clopidogrel had HPR at 1 week.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Ottawa Heart Institute.

More:
World's first bedside genetic test

Public release date: 29-Mar-2012 [ | E-mail | Share ]

Contact: Elizabeth Lynch elynch@marchofdimes.com 914-997-4286 March of Dimes Foundation

CHARLOTTE, NC -- A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.

Harry (Hal) Dietz, MD, the Victor A. McKusick Professor of Institute of Genetic Medicine and Professor of Pediatrics, at Johns Hopkins University School of Medicine and Howard Hughes Medical Institute Investigator, will receive the March of Dimes/Colonel Harland Sanders Award for Lifetime Achievement in the field of genetic sciences. Dr. Joe Leigh Simpson, senior vice president for Research and Global Programs of the March of Dimes, will present the award to Dr. Dietz today during the annual Clinical Genetics Meeting of the American College of Medical Genetics at Charlotte Convention Center.

Marfan syndrome is an inherited connective tissue disorder that affects about 1 in 5,000 people. The syndrome is caused by a genetic defect which causes overgrowth of the body's long bones and affects the tissue that strengthens the body's structures, including the skeletal system, cardiovascular system, eyes, and skin.

Those who have the syndrome tend to be tall with arms and legs much longer than expected for their height. Also, in those with Marfan syndrome, the aorta, the main blood vessel that takes blood from the heart to the body, may stretch or become weak, leading to an aneurysm.

In 1991, Dr. Dietz was a member of the team that identified the gene for Marfan syndrome. In 2006, his team's research showed that an FDA-approved high blood pressure medication, losartan, prevented and reversed aortic enlargement in mice with Marfan syndrome.

Dr. Dietz received his medical degree from the State University of New York Upstate Medical Center in 1984. He joined Johns Hopkins University Hospital in 1984 as a pediatric resident, became a Fellow in Cardiology there 1988, went on to pursue his post doctorate work at John Hopkins as wells and continues his research there today.

He was named the Richard Starr Ross Research Scholar, he received the Richard D. Rowe Award for outstanding research in Pediatric Cardiology, the Young Investigator Award, Society for Pediatric Research, and the Antoine Marfan Award, from the National Marfan Foundation. Dr. Dietz also is a member of the Board of Governors, National Human Genome Research Institute, a member of the American Society for Pediatric Research and the American Society for Clinical Investigation.

###

Go here to read the rest:
Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored

Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, NYSE and Amex. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.

Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Morningstar, Inc.

Yahoo! - ABC News Network

View original post here:
AKESOgen and London Genetics International Alliance to Enhance Drug Development Through Pharmacogenetics and Related ...

AMES, Iowa, March 29, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported financial results for its quarter and year ended December 31, 2011, and provided an update on the progress of its clinical development programs.

"2011 was a pivotal year for NewLink," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink. "By successfully completing our initial public offering and raising additional private money, we raised adequate capital to allow us to complete patient enrollment in our pivotal Phase three pancreatic cancer clinical trial as well as advancing four other cancer immunotherapies into or further into clinical trials addressing patients with significant unmet medical needs."

Full Year 2011 Financial Results

Financial Guidance

NewLink expects to end 2012 with about $20 million in cash, cash equivalents and marketable securities. NewLink anticipates that this capital should allow it to fund its operations through 2013 based on its current operating plans.

2011 Key Accomplishments and 2012 Goals

Upcoming Activities

NewLink expects to present at the following investor conferences:

NewLink expects to present at the following oncology and pharmacology meetings:

Today's Conference Call and Webcast Reminder

Read this article:
NewLink Genetics Corporation Reports Fourth Quarter and Full-Year 2011 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics,Inc. (OTCQB: ILIU.PK - News) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2011.

We continued to develop our business in 2011. Our genetic testing revenue has grown by more than forty percent this year over last year as we added new partnerships for distribution of our tests. In addition, our collaboration with Stanford University continued with an extension study whose results showed that the genetic patterns identified by our Weight Management Test can help individuals lose more weight when diets are selected based on genotype, said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. Most importantly, we have advanced our large, clinical program with our partners the University of Michigan and Renaissance Health and completed enrollment of over 5,400 patients in a landmark pivotal study. Positive results from the study would set the PST Genetic Test as a key determinant of periodontal disease risk. This study has the potential to create new insurance benefit programs for insurers and lead to reimbursement for the test.

2011 Financial Highlights

The Company reported revenues of $2.9 million and a loss from continuing operations of $5.2 million, or $(0.14) per basic and diluted common share, for the year ended December31, 2011, compared to revenues in 2010 of $2.0 million and a loss from continuing operations of $6.5 million, or $(0.18) per basic and diluted common share. The revenue increase is primarily attributable to sales of the Companys Inherent Health brand of genetic tests through the Amway Global sales channel.

Research and development expenses were $1.4 million for each of the years ended December 31, 2011 and 2010.

Selling, general and administrative expenses were $4.7 million for the year ended December 31, 2011, compared to $5.5 million for the year ended December 31, 2010. The decrease is primarily attributable to decreases in compensation, product development, promotion and consulting expenses, and is partially offset by increased sales commissions paid to Amway Global as part of our Merchant Network and Channel Partner Agreement.

Fourth Quarter Results

Revenue for the quarter ended December31, 2011 was $0.6 million, compared to $0.5 million for the same period in 2010. The increase is primarily attributable to genetic testing revenue as a result of sales through the Amway Global sales channel.

Research and development expenses were $0.4 million for the quarters ended December31, 2011 and 2010.

Read the rest here:
Interleukin Genetics Reports Fourth Quarter and Year End 2011 Financial Results

The Catholic Church has never had a particularly easy relationship with science. After all, this is the institution that sentenced Galileo Galilei as a heretic for his theories on the universe during the Roman Inquisition. Two thousand years later, the church forgave Galileo and called the whole misunderstanding a tragic mutual incomprehension but it remains safe to say the Vatican doesnt have a great track record when it comes to empirical open-mindedness.

So onlookers were surprised when the Vatican announced it would be hosting a global conference on the highly controversial issue of stem-cell research in Rome over four days in late April. The church held a similar conference in 2010 and 2011, which focused on its recommendation that stem-cell research should be limited to adult cells that can be harvested from live donors, not embryonic cells that destroy the source. But this years conference schedule featured some of the worlds foremost experts in embryonic research as keynote speakersleading some scientists to think that the Vatican might actually be looking for enlightenment on the topic.

That was not exactly case. Instead, the Vatican seems to have hoped that by including embryonic researchers in the program, it would appear that these scientists actually endorsed the Vaticans stance.

It might have worked to some extent, but after some of the speakers declined to censor their speeches, the Vatican abruptly canceled the conference altogether. According to the conference website, the event was canceled due to serious economic and logistic-organizational reasons that have completely jeopardized the success of the 3rd International Congress on Responsible Stem Cell Research. The scientists who were planning to attend say they are being stifled instead. I think the only interpretation is that we are being censored, Alan Trounson, president of the California Institute for Regenerative Medicine in San Francisco, said in a statement. It is very disappointing that they are unwilling to hear the truth.

Just what was the Vatican thinking? Inviting embryonic stem-cell researchers to a conference and then denying them the right to talk about their field of expertise was a major gamble. Had the speakers agreed to avoid reference to embryonic research, it would have given the disingenuous impression that they endorse the Holy Sees recommendation on adult stem-cell research only. Did the Vatican really think they could control the scientific community? Apparently so. Father Scott Borgman of the Pontifical Academy for Life, which co-organized the conference, had reportedly asked the speakers to limit their discussions to adult stem-cell research only. George Daly, a leading embryonic researcher with the Childrens Hospital in Boston, says he was actually told not to make embryonic researchhis field of expertisea focal point of his talk. When he told Borgman that he would still be touching on the topic in a historical context, higher-ups in the Vatican reportedly panicked. I had been encouraged to think that the Congress would be a forum for discussion of many areas of common interest to the Vatican and stem cell scientists, regardless of the disagreements over embryonic stem cells, Daly told The Daily Beast. We should all agree that clinical trials of new medical treatments based on stem cells should proceed according to rigorous principles to ensure patients are kept as safe as possible and free from exploitation. And we should all agree that premature claims of therapeutic efficacy and direct marketing of unproven interventions to vulnerable patients is a threat to legitimate attempts to develop experimental stem cell medicines.

Pope Benedict looks on during the mass in solemnity of the chair of St. Peter with new Cardinals in St. Peter's basilica at the Vatican on February 19, 2012. The Vatican stands by its decision to cancel the controversial conference as having a purely business motive. , Alberto Pizzoli, AFP / Getty Images

With the cancelation of the event, discourse between the two diverse entities will not have a venue. One Vatican official told the Catholic News Service that many of the Vaticans leaders were secretly glad the conference failed. I am infinitely relieved that the church has avoided a major blunder which would have confused the faithful for decades to come, the unnamed source said. The Holy Spirit has certainly shown to be present through those faithful members who drew attention to the ambiguity of the choice of speakers. I hope and pray that a review will be affected of the basis on which these congresses are planned.

Some stem-cell researchers are also relieved the conference wont go on. I personally am very uncomfortable with a scientific meeting run by a church, and one at which only certain types of science and scientists are allowed to attend, blogged Paul Knoepfler, an associate professor of Cell Biology and Human Anatomy at UC Davis School of Medicine who blogs about stem cell research at IPCell.com. Also I cant help but wonder, what would be the reaction if someone like Daley spent a few minutes of his talk discussing his embryonic cell research in a very nonconfrontational way? Would he be tasered or drop through some trap door straight to Hell?

Still, Knoepfler was hopeful. I view the canceled Vatican stem-cell meeting as a missed opportunity for a very much needed, open dialogue about stem cells, he told The Daily Beast. More specifically, I believe the reasons for the cancellation reflect an anti-scientific attitude by the highest level of Vatican leaders. More simply put, the attitude might be summed up by the phrase If you do not think like us, you are not welcome at our meeting, and well go so far as to cancel the whole thing to avoid your presence.

Inviting embryonic stem-cell researchers to a conference and then denying them the right to talk about their field of expertise was a major gamble.

Read more from the original source:
Stem Cells: Galileo 2.0?

MOUNTAIN VIEW, California, March 29, 2012 /PRNewswire/ --

After witnessing a downtrend for several years, revenues in the U.S. nuclear medicine and positron emission tomography (PET) imaging systems market finally pivoted in 2010. New radiotracers and technologies are expanding the clinical scope and customer base of nuclear medicine and PET imaging. As a result, declines in retrenching areas of the market are poised to be offset by strong growth in emerging end-user market segments.

Nuclear medicine and PET are molecular imaging modalities, providing data pertaining to molecular alterations, which are the origin of disease. In contrast, classical imaging modalities, such as X-ray, reveal only the changes in anatomy, which are essentially the end effects of disease and its associated molecular alterations.

New analysis from Frost & Sullivans (http://www.medicalimaging.frost.com [http://www.frost.com/prod/servlet/svcg.pag/HCIM ]) U.S. Nuclear Medicine and PET Imaging Systems Market research finds that the market earned revenues of $552.4 million in 2010 and estimates this figure to reach $841.8 million in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"The unique ability of nuclear medicine and PET to enable characterization of biological processes at the cellular and molecular levels is bringing increasing attention to these imaging modalities as medicine evolves toward more personalized forms of treatment, " said Frost & Sullivan Industry Analyst Roberto G. Aranibar. "This powerful capability of nuclear medicine and PET will become increasingly relevant as personalized healthcare becomes mainstream practice in modern medicine."

Recognizing this advantage, industry participants are gravitating toward this area of imaging. As a result, nuclear medicine and PET imaging systems market revenues experienced a growth upsurge in 2010, and they are expected to continue growing for the next several years.

Molecular imaging has been a key enabling factor for treatment that is selected according to a patients unique disease state. For example, in cancer treatments, numerous chemotherapy options are available, and a patients response to a particular treatment can vary considerably based on the specific molecular characteristics of the cancer. With molecular imaging, however, clinicians can determine which characteristics are present in a cancer and use this information to make the most appropriate treatment decision on a patient-by-patient basis.

Ongoing challenges surrounding the state of the economy as well as changes in healthcare policy and reimbursement are forcing more private practice physicians and independent imaging centers to opt for affiliation with larger provider organizations. This shift in the healthcare provider landscape has led to rapidly diminishing revenues within the private practice cardiology market, which formerly accounted for a significant proportion of revenues in the more mature and established nuclear medicine segment of the market.

Naturally, the evolving healthcare provider landscape has led to changes in the types of imaging systems that are being demanded in the marketplace. For example, the need for dedicated cardiac scanners appears to be diminishing, as more cardiologists become affiliated with larger institutions that often benefit more from general-purpose scanners with a broader scope of clinical application.

Original post:
Frost & Sullivan: U.S. Nuclear Medicine and PET Imaging Systems Market Witnessed a Rebound in 2010, With PET Blazing ...

UQ research with the potential to develop improved treatment options for spinal cord injuries has received funding for four years from SpinalCure Australia.

Dr Marc Ruitenberg from UQ's School of Biomedical Sciences has been awarded a prestigious Career Development Fellowship to support ongoing research into the inflammatory response to spinal cord injury.

There is overwhelming evidence that the inflammatory response to spinal cord injury is a double-edged sword," Dr Ruitenberg said.

"Some aspects can cause additional damage while others appear to be contributing to tissue repair.

Our ultimate research goal is to understand which aspects of the inflammatory process worsen injury outcomes, to enable the development of new and effective anti-inflammatory therapies that can improve recovery.

Dr Ruitenberg's laboratory is concentrating on the innate immune system because of the dominant role that it is thought to play in the inflammatory pathology associated with spinal cord injury.

He is also actively involved in the development of ultra-high field magnetic resonance imaging (MRI) techniques to study the injured spinal cord and to aid better translation of promising research findings from the laboratory bench to the clinic.

This fellowship is a major boost to the research activities in Dr Ruitenberg's laboratory and will accelerate the development of better treatment options for spinal cord injury.

The award is being funded in partnership with The University of Queensland for 2012-2015.

Media: UQ School of Biomedical Sciences, Avril Johnston-Craig, 07 3365 1536, 0408 160 784, a.johnstoncraig@uq.edu.au

Follow this link:
Spinal cord injury research receives funding boost

LOS ANGELES Blocking "don't destroy me" signals that normally sit on the surface of tumor cells and render them resistant to immune-cell attack slows the growth of a broad range of human cancers when they're implanted in mice, researchers have found.

The approach, reported by immunologists at the Stanford University School of Medicine, was effective against ovarian, breast, colon, bladder, liver, prostate and brain cancer cells. If the work can be repeated in people, the approach may someday help doctors marshal defender cells in patients' own bodies to fight cancers, the researchers said.

Key to the work is a cell protein called CD47, which is already being investigated in the treatment of leukemia.

CD47 sits on cell membranes and communicates with various immune cells, including macrophages, which gobble up foreign invaders in the body. It plays an important role in the normal life cycle of healthy red blood cells, telling macrophages to leave the cells alone.

In the study, the scientists injected the animals with antibodies that bind to CD47 and block out its protective signal.

"If we can block this signal, we can get the immune system to eat (the cancer cells) up," said Stephen Willingham, a postdoctoral researcher in the laboratory of immunologist Dr. Irving Weissman at Stanford and first author of a paper about the work.

The Stanford team examined cancer cells removed from patients with a variety of types of solid tumors. It found that CD47 studded the membranes of almost all of the cancer cells in their sample, suggesting that it is a molecule common to all cancers.

Placing the cells in lab dishes, the team administered an antibody: a protein that binds to CD47 and blocks it from warding off immune system cells. Macrophages ate the cells.

The researchers then implanted human tumor cells in mice for further study. They allowed the cancers to grow, and administered the antibody against CD47.

Antibody treatment inhibited the growth of almost all of the solid tumors and was able to wipe out some smaller cancers altogether, according to the report, which was published Monday in the journal Proceedings of the National Academy of Sciences.

See the original post:
Cancer research focuses on cell protein

NEW YORK, March 28, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, today announced that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering. All of the shares and warrants in the offering will be sold by NeoStem. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities will be issued pursuant to a prospectus supplement filed as part of an effective registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC).

Maxim Group LLC is acting as book-runner of the offering.

A shelf registration statement relating to the securities was filed with the SEC, which became effective on June 13, 2011. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174 or via telephone at (212) 895-3685.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. NeoStem intends to file a preliminary prospectus supplement relating to the offering with the SEC, which will be available along with the prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business and medical strategy, including with respect to the development of AMR-001 and other cell therapies and its divestiture of its interest in Suzhou Erye Pharmaceutical Co., Ltd. about which no assurance can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2012 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

More:
NeoStem Announces Proposed Public Offering of Common Stock and Warrants

27-03-2012 15:05 New IBM Big Data Supercomputer Center Rutgers University Team Technology News Blue Gene/P. Rutgers Teams With IBM to Build Powerful High-Performance Computing Center In New Jersey. Rutgers today formally launched a high-performance computing (HPC) HPC center at the university focused on the application of "Big Data" analytics in life sciences, finance, and other industries. The center is aimed at improving the economic competitiveness of New Jersey's public and private research organizations.

See the original post here:
IBM Blue Gene/P Supercomputer New Big Data Center Rutgers University Team - Video

Speeders and others nabbed for moving violations would have to hand over an extra $1, $5 or $10 for spinal cord injury research at UAB under a bill bill in the Alabama Legislature.

The bill -- named for University of South Alabama student T.J. Atchison, who was paralyzed in a 2010 car accident -- is expected to raise up to $500,000 a year to help find a cure for spinal cord injuries. It has passed the Alabama Senate and a version has been sponsored in the state House. On Wednesday its supporters toured the Spain Rehabilitation Center at the University of Alabama at Birmingham, which would administer the money.

"I've told T.J. and his mom and dad all this time that if we get this passed it would be a miracle," said state Sen. Marc Keahey, D-Grove Hill, who sponsored the bill. "Now I think the miracle's going to happen."

The T.J. Atchison Spinal Cord Injury Act was developed with help from Roman Reed, who persuaded California lawmakers to set aside millions for spinal cord injury. Since its passage in 1999, the bill named for Reed has raised more than $125 million for research.

If it becomes law, the Atchison act would charge an extra $1 for basic moving violations, $5 for aggravated violations such as reckless driving or following too closely and $10 for DUIs. Traffic accidents are the leading cause of spinal cord injuries, Reed said.

The money would be administered by Candace Lloyd, a UAB researcher. She said the funded research would have two main aspects: on finding a cure and seeking to alleviate the side effects that paralysis patients experience.

Follow this link:
Bill in Alabama Legislature would bring spinal cord research money to UAB

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com

Read the original here:
Stem cell therapy for the repair of myocardium in heart failure patients - Video

The Myriad case has been closely watched by the biotechnology industry, with some insiders suggesting that a ruling against gene patenting could have a devastating effect on future innovation.

The Supreme Court ruled last week in a separate case involving medical diagnostics that companies cannot patent observations about a natural phenomenon. On Monday, it asked the lower court to revisit the Myriad case to view how it may or may not relate to that decision.

The move is expected to delay a verdict in the Myriad case by as much as several years. In the case of the individual company, that may give it enough time to benefit from the use of its contested patents. Shares in Myriad rose over 3 percent.

"Our intellectual property consultant could potentially see a scenario where the case doesn't move its way back to the Supreme Court for another 2 to 3 plus years, keeping the BRACAnalysis franchise safe from competition," said Junaid Husain, a research analyst for Dougherty & Co.

Women who test positive using Myriad's gene test, called BRACAnalysis, have an 82 percent higher risk of developing breast cancer and a 44 percent higher risk of ovarian cancer in their lifetimes. Such tests could help determine a future course of therapy.

The appeals court by a 2-1 vote had ruled the genes isolated by the company could be patented because Myriad is testing for distinctive chemical forms of the genes, and not as they appear naturally in the body. The dissenting judge said the genes could not be patented just because they were isolated from the body.

The patents granted to Myriad give the company the exclusive right to perform the genetic tests. The appeals court in its ruling in July also found that Myriad's method for screening potential therapies can be patented.

The appeals court had overturned a ruling by a federal judge in New York that the genes could not be patented.

HOW BIG A HURDLE?

Michael Yee, biotech analyst for RBC Capital Markets, said the Supreme Court not taking up the case on Monday was positive for the biotechnology industry.

See the original post:
Supreme Court throws out human gene patents

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- A novel method for printing human cells onto surfaces in defined patterns can help advance research on tissue engineering and regeneration, as described in an article in Tissue Engineering, Part C, Methods, a peer-reviewed journal from Mary Ann Liebert, Inc (http://www.liebertpub.com). The article is available free online at the Tissue Engineering website (http://www.liebertpub.com/ten).

"Cell printing is one of the breakthrough technologies that will make the application of stem cells for tissue engineering feasible," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands.

Yu Fang and colleagues, University of Michigan, Ann Arbor, combined two microscale techniques to dispense and position cells in a variety of patterns. They then demonstrated the ability to use these 3-dimensional cell systems to monitor cell signaling events known to have a role in the growth, proliferation, and metastasis of cancer cells. The authors describe the use of sound waves to deliver microdroplets of cells and polymer-based phase separation to control cell placement in the article "Rapid Generation of Multiplexed Cell Co-Cultures Using Acoustic Droplet Ejection Followed by Aqueous Two-phase Exclusion Patterning." (http://online.liebertpub.com/doi/abs/10.1089/ten.TEC.2011.0709)

###

About the Journal

Tissue Engineering (http://www.liebertpub.com/ten) is an authoritative peer-reviewed journal published monthly in print and online in three parts: Part A--the flagship journal; Part BReviews; and Part CMethods. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website (http://www.liebertpub.com/ten).

About the Company

Mary Ann Liebert, Inc.(http://www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy and HGT Methods, and Biopreservation and Biobanking. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at Mary Ann Liebert Inc. (http://www.liebertpub.com).

The rest is here:
Innovative cell printing technologies hold promise for tissue engineering R&D

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- Online romance scams, a new form of cybercrime, is under-reported and increasing, and has victimized an estimated 230,000 people in England, costing them nearly $60 billion a year, according to an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

"This crime is very serious and unfortunately often overlooked. The costs to the victim are both hidden (emotional) and more visible (monetary)," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior and Social Networking, from the Interactive Media Institute, San Diego, CA.

Online dating scammers pretend to initiate a romantic relationship through online dating services and then defraud their victims of large sums of money over a period of months or longer. Monica Whitty, University of Leicester, UK, and Tom Buchanan, University of Westminster, London, UK, document the rapid growth in these serious crimes and how cybercriminals pursue and steal from their victims. They describe the devastating financial and emotional losses the victims suffer.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is an authoritative peer-reviewed journal published monthly in print and online that explores the psychological and social issues surrounding the Internet and interactive technologies. Complete tables of content and a sample issue may be viewed online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

About the Company

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website at http://www.liebertpub.com.

Continued here:
Online dating scammers looking for money, not love

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as "silent mutations," which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described today in the journal Nature, the speed change is caused by information contained in what are known as redundant codons small pieces of DNA that form part of the genetic code. They were called "redundant" because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

"The genetic code has been thought to be redundant, but redundant codons are clearly not identical," said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular andMolecular Pharmacology.

"We didn't understand much about the rules," he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, "NP" instead of "No problem." They both mean the same thing, but one is faster to thumb than the other.

How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was.

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called "ribosome profiling," which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

Ribosome profiling takes account of gene activity by pilfering from a cell all the molecular machines known as ribosomes. Typical bacterial cells are filled with hundreds of thousands of these ribosomes, and human cells have even more. They play a key role in life by translating genetic messages into proteins. Isolating them and pulling out all their genetic material allows scientists to see what proteins a cell is making and where they are in the process.

See the article here:
Researchers discover new layer of genetic information that helps determine how fast proteins are produced

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Raymond MacDougall macdougallr@mail.nih.gov 301-402-0911 NIH/National Human Genome Research Institute

Farmers in the highlands of southern Ethiopia scratch out a subsistence living from the region's volcanic red clay. The soil supports the farms, but fine-grained, volcanic rock particles in the dirt threaten the farmers and their families. Continual exposure of bare feet to the volcanic soil causes 1 in 20 people to develop a painful inflammation of the lower extremities that, over time, leads to foot disfigurement. Doctors call it podoconiosis. The locals call it mossy foot. And those affected suffer social stigma as well as debilitating discomfort.

Now, researchers think they know why some 4 million people in at least 10 countries worldwide develop this incapacitating condition. One-fifth carry genetic variants that cause their immune system to react to the volcanic dust. This disease-producing response, triggered by exposure from the lack of shoes, provides a dramatic example of the interaction between genes and the environment.

Writing in the March 29, 2012 New England Journal of Medicine, an international team that includes researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, describes the genetic link that turns dirt into a toxin.

"This study draws attention to a neglected tropical disease with a devastating impact on poor people and their communities," said NHGRI Scientific Director Dan Kastner, M.D., Ph.D. "It demonstrates the global reach of genomics research into the lives of people in parts of the world where endemic diseases very often go unchecked."

Doctors have known for a long time that podoconiosis runs in families and that continual exposure to volcanic soil triggers it. Wearing shoes and socks, or even washing off the dirt, prevents the condition. But doctors have been perplexed that only some people develop the disease, while others with the same environmental exposure are spared.

To sort this out, the international collaborators conducted a genome-wide association studyor GWASanalyzing DNA from 194 volunteers from the Ethiopian highlands affected by podoconiosis, along with DNA from another 203 unaffected individuals from the same region. The researchers collaborated with field workers from the non-profit Mossy Foot Treatment and Prevention Association in southern Ethiopia to collect the data and samples.

The researchers generated a dataset from study-participant DNA, screening more than 550,000 single-nucleotide polymorphisms (SNPs), which are sites in an individual's DNA that contain a different chemical base when compared to a standard reference human genome sequence. They found significant podoconiosis association for eight SNPs within or nearby a stretch of DNA on chromosome 6, called the HLA class II locus.

The researchers performed a second validation step, called a family-based association study, using DNA samples from 202 sets of child-parent trios from affected families. The researchers detected six SNPs that showed significant associationthose that mapped to HLA class II region genes and most strongly associated with podoconiosis in the GWAS, validating the GWAS results.

Read more:
Researchers identify genetic basis of tropical foot and leg lymphedema

Newswise A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells including the speed with which proteins are made.

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as silent mutations, which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described today in the journal Nature, the speed change is caused by information contained in what are known as redundant codons small pieces of DNA that form part of the genetic code. They were called redundant because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

The genetic code has been thought to be redundant, but redundant codons are clearly not identical, said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular and Molecular Pharmacology.

We didn't understand much about the rules, he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, NP instead of No problem. They both mean the same thing, but one is faster to thumb than the other. How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was. Ribosome structure

The structure of a ribosome

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called ribosome profiling, which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

Original post:
New Layer of Genetic Information Discovered

ScienceDaily (Mar. 28, 2012) A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells -- including the speed with which proteins are made.

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as "silent mutations," which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described March 28 in the journal Nature, the speed change is caused by information contained in what are known as redundant codons -- small pieces of DNA that form part of the genetic code. They were called "redundant" because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

"The genetic code has been thought to be redundant, but redundant codons are clearly not identical," said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular and Molecular Pharmacology.

"We didn't understand much about the rules," he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, "NP" instead of "No problem." They both mean the same thing, but one is faster to thumb than the other.

How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was.

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called "ribosome profiling," which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

See original here:
New layer of genetic information helps determine how fast proteins are produced

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP

The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Earlier this month the company filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. "This reverse stock split, which should better align the company's capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space," said Gary Rabin, chairman and CEO of ACT.

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. For the year ended December 31, 2011, PharmAthene recognized revenue of $24.3 million, compared to $21.0 million in 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

See the original post here:
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com

Read the original post:
Stem cell therapy for the repair of myocardium in heart failure patients - Video

Arkansas State University-Newport will host a Bone Marrow Donor Drive on campus Thursday, March 29 from 10am until 7pm and Saturday, March 31 from 9am until 1pm in the Student/Community Center, Merchants & Planters Insurance and Investments room. A bone marrow transplant is a lifesaving treatment for people with leukemia, lymphoma and many other diseases. First, patients undergo chemotherapy and sometimes radiation to destroy their diseased marrow. Then a donor's healthy blood-forming stem cells are transfused directly into the patient's bloodstream, where they can begin to function and multiply. For a patient's body to accept these healthy cells, the patient needs a donor who is a close match. Seventy percent of patients cannot find a matching donor within their family and depend on the national registry to find an unrelated bone marrow donor. Even with a registry of millions, 6 out of 10 patients NEVER receive the lifesaving transplant they need. Donors of all ethnicities are needed to change this. To see if you can be a bone marrow donor and to read about the process of testing and donating, go to http://www.dkmsamericas.org and click on Get Educated.

Read this article:
ASUN to host Bone Marrow Donor Drive

Volunteers will stake out locations all over Athens today from the downtown Waffle House at 2 a.m., to Athens City Hall at 4 p.m. to encourage people across the city to register for a bone marrow donor list in the hopes of finding a match for two sick locals.

The need is even more urgent because former Clarke County school nurse Thomasene Smith and Athens Academy sixth-grader Kajal Patel are minorities, said Caitlin Martin, a representative of Be The Match, the national bone marrow donor registry program. Be The Match, the University of Georgia, the Omni Club and Athens Academy have joined together to host a marathon, continuing today at locations across Athens, to help find donors for Smith and Patel by signing more people to the donor registry list.

Minorities have such a poor chance of finding a match because more than 90 percent of the people signed up for the registry are white, Martin said.

Race matters when trying to find a match for a bone marrow donation, and often, family members arent the best fit, Martin said.

Only 30 percent of our patrons have matches within their family, she said.

Holding the marathon for Smith and Patel will help people of minority groups learn that sick people need them to register for the bone marrow donor list, said Kelin Johnson, Omni Ambassador and former Georgia defense back.

Once people know that race matters when finding a bone marrow donor, more donors likely will come forward, Johnson said.

I think it just comes from a lack of education or awareness, he said.

Potential donors might also shy away from registering because they think the process will hurt too much, Martin said.

One of the biggest myths is that its painful, and thats not true, she said.

View original post here:
Volunteers work 'round the clock to find bone marrow donors

Displaying rare unanimity on an issue, the full U.S. 9th Circuit Court of Appeals on Tuesday rejected a request by the federal government thatit reconsidera rulingthat most bone marrow donors can be compensated for providing life-saving marrow stem cells from their blood.

A three-judge panel of the appeals court ruled on Dec. 1 that the process of harvesting marrow cells by filtering a donor's blood wasn't covered by the 1984 National Organ Transplant Act's prohibitionof payment for organs or organ parts.The statute was enacted by Congress before the blood-filtering process was developed and donors were subjected to painful and medically risky surgical extraction of marrow by insertion of a siphoning needle into the hip bone. Compensation for that form of donation remains illegal.

Atty. Gen. Eric H. Holder Jr., on behalf of the federal government, petitioned the court in Januaryfor a new hearing by an 11-judge panel. Department of Justice lawyers argued that the December ruling ignored the clear intent of Congress to prevent money from influencing donation decisions.

The 9th Circuit panel said in its latest ruling thatall 25 active judges on the court were informed of the government's request and none called for a vote on it, signaling their agreement with the December decision. That unusualaccord among the judges who span a broad ideological spectrum might also indicate that the U.S. Supreme Court will be unlikely to take the case for review.

The lawsuit challenging the ban on bone marrow compensation was brought by a group of cancer patients and their families, as well as a marrow transplant specialist and a California nonprofit organization, MoreMarrowDonors.org, aiming to expand the registry of available donors by offering up to $3,000 in housing assistance or scholarships for promising genetic matches.

Violation of the organ transplant act's prohibition on sales of organs or parts thereofcarries heavy fines and up to five years in prison.The 1984 act defined bone marrow as an organ part, while the 9th Circuit's ruling said it was a blood part and not subject to theban on compensation.

ALSO:

Mega Millions lottery jackpot soars to $363 million

Trayvon Martin: L.A. rallies voice outrage at shooting

First defendants graduate from L.A. County Veterans Court

Read the original:
Appeals court stands united on compensation for bone marrow donors